These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37149113)

  • 1. Current therapeutic delivery approaches using nanocarriers for the treatment of tuberculosis disease.
    Biswas B; Misra TK; Ray D; Majumder T; Bandyopadhyay TK; Bhowmick TK
    Int J Pharm; 2023 Jun; 640():123018. PubMed ID: 37149113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nano vs Resistant Tuberculosis: Taking the Lung Route.
    Sharma D; Pooja ; Nirban S; Ojha S; Kumar T; Jain N; Mohamad N; Kumar P; Pandey M
    AAPS PharmSciTech; 2023 Dec; 24(8):252. PubMed ID: 38049695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanocarrier-based interventions for the management of MDR/XDR-TB.
    Mustafa S; Pai RS; Singh G; Kusum Devi V
    J Drug Target; 2015 May; 23(4):287-304. PubMed ID: 25766078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
    Khusro A; Aarti C; Barbabosa-Pliego A; Salem AZM
    Microb Pathog; 2018 Jan; 114():80-89. PubMed ID: 29174699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities.
    Patil K; Bagade S; Bonde S; Sharma S; Saraogi G
    Biomed Pharmacother; 2018 Mar; 99():735-745. PubMed ID: 29710471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis.
    Garg T; Rath G; Murthy RR; Gupta UD; Vatsala PG; Goyal AK
    Curr Pharm Des; 2015; 21(22):3076-89. PubMed ID: 26027577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of recent advances in anti-tubercular drug development.
    Umumararungu T; Mukazayire MJ; Mpenda M; Mukanyangezi MF; Nkuranga JB; Mukiza J; Olawode EO
    Indian J Tuberc; 2020 Oct; 67(4):539-559. PubMed ID: 33077057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis.
    Rath G; Pradhan D; Ghosh G; Goyal AK
    Curr Pharm Des; 2021; 27(17):2026-2040. PubMed ID: 33634753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
    Reddy DS; Kongot M; Kumar A
    Tuberculosis (Edinb); 2021 Mar; 127():102050. PubMed ID: 33540334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
    Singh J; Garg T; Rath G; Goyal AK
    Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid derivatives and their anti-tubercular activity.
    Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
    Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of collinin isolated from the leaves of Zanthoxylum schinifolium against multidrug- and extensively drug-resistant Mycobacterium tuberculosis.
    Kim S; Seo H; Mahmud HA; Islam MI; Lee BE; Cho ML; Song HY
    Phytomedicine; 2018 Jul; 46():104-110. PubMed ID: 30097109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
    Rajkhowa S; Deka RC
    Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance pattern of multi-drug resistant strains of Mycobacterium tuberculosis and characteristics of patients with multi-drug resistant tuberculosis.
    Moisoiu A; Mitran CI; Mitran MI; Huhu MR; Ioghen OC; Gheorghe AS; Tampa M; Georgescu SR; Popa MI
    Roum Arch Microbiol Immunol; 2016; 75(1-2):25-31. PubMed ID: 29616530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Insights into the Chemistry and Antitubercular Potential of Benzimidazole and Imidazole Derivatives.
    Parwani D; Bhattacharya S; Rathore A; Mallick C; Asati V; Agarwal S; Rajoriya V; Das R; Kashaw SK
    Mini Rev Med Chem; 2021; 21(5):643-657. PubMed ID: 33138762
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.